Healthcare Jul 22, 2021 12:01 PM (GMT+8) · EqualOcean
Recently, Beijing geenga Technology Co., Ltd., a cancer precision medical enterprise, announced the completion of round C financing with a total amount of about 750 million yuan. At present, the funds are in place. This round of financing is led by CCB international, with investors including Dachen Caizhi, Jinmao capital, GGV Jiyuan capital, etc. This round of financing will be used to further promote the innovative R & D, registration declaration and clinical services of gene plus tumor large panel gene detection, tumor early screening and other products, as well as the cooperation with innovative pharmaceutical companies in the field of cancer in the collaborative development of new drugs.